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Multiple myeloma is an uncommon neoplasm of plasma cells
affecting mainly the elderly; it is rare under the age of 50 years.
Each year in England and Wales, approximately 1800 cases are
registered in men (1.5% of all malignancies) and 1500 in women
(1.2% of all malignancies). Incidence has increased steadily since
the 1980s in both sexes in many countries, including England and
Wales (Coleman et al, 1993; Quinn et al, 2001). Incidence is slightly
higher in men, and it has risen by approximately 12% in both sexes
since the mid-1980s to reach 6.1 per 100000 per year in men and
5.5 in women by 1999. No marked socioeconomic gradient in
incidence has previously been reported in England and Wales, but
the most deprived fifth of the population provides a striking
exception to the overall trend in the 1990s: incidence rates in this
group increased very little in either sex, and by 1999, annual
incidence was 20–25% lower than in the other four deprivation
groups (4.5 and 4 per 100000 in men and women, respectively).
The aetiology of myeloma is unknown, although exposure to
ionising radiation is a cause (IARC, 2000) and occupational
exposure to chemicals, such as ethylene oxide, styrene and vinyl
chloride have been suggested as risk factors (Blair and Kazerouni,
1997; Lynge et al, 1997; Stellman, 1998).
Myeloma is characterised by a malignant clone of plasma
cells invading bone marrow, with high serum or urine levels
of monoclonal immunoglobulin (usually a g-globulin), and lytic
bone lesions. It is often preceded by a latent monoclonal gammo-
pathy of uncertain or undetermined clinical significance, which
may last for years before evolving into malignant myeloma
proper. Monoclonal gammopathy of uncertain or undetermined
clinical significance may be diagnosed incidentally from routine
examination of serum or a blood film, and in the minority
of patients who do go on to develop myeloma, the date of diagnosis
– and thus the recorded duration of survival – will depend on the
frequency and diagnostic intensity of clinical follow-up (Berrino
et al, 1995). Part of the increase in incidence may be attributable to
the improved sensitivity of diagnostic tests, but environmental
exposure to toxins may also underlie a real increase (Richardson
et al, 2004).
Myeloma comprised 96% of the malignant monoclonal gammo-
pathies throughout the period 1986–1999, whereas plasmacytoma
accounted for most of the remainder.
Almost 40000 adults were registered with multiple myeloma
in England and Wales during the 14-year period 1986–1999.
Approximately 18% of patients otherwise eligible for survival
analysis were excluded, mostly (13%) because their recorded
duration of survival was zero (date of diagnosis same as the date of
death). Some of these patients will have been diagnosed on the day
of death, but in many cases the cancer registration was based solely
on the death certificate; hence, the date of diagnosis was unknown.
It was not possible to distinguish these cases in the available data
and all patients with ‘zero survival’ were thus excluded. The vital
status of 1.6% of eligible patients was unknown on 5 November
2002, when the data were extracted for analysis, and a further 3%
were excluded because myeloma was not their first primary
malignancy. The distribution of patients in these categories was
fairly stable over the period 1986–1999 and similar in all
deprivation groups (data not shown); hence, the exclusions are
unlikely to have had a large impact on time trends or the
deprivation gradient in survival.
SURVIVAL TRENDS
For patients diagnosed during 1996–1999, relative survival was
approximately 62% at 1 year and 25% at 5 years, whereas 10-year
survival was only 10–11% for patients diagnosed during the early
1990s (Table 1). Survival is now 1–2% higher in men, but the
differences are not significant. After adjustment for changes in the
distribution of patients by deprivation category, 5-year survival is
seen to have risen significantly over the 14-year period 1986–1999,
by an average of approximately 5% every 5 years (4.4% in men,
5.8% in women). In fact, most of the increase occurred during the
1990s (Figure 1). One-year survival also increased significantly
for men (3.8% every 5 years) to 62.9% (Table 1, Figure 1), but
the small increase for women was not significant. There was no
significant increase in 10-year survival between patients diagnosed
in the late 1980s and those diagnosed in the early 1990s.
Hybrid analysis (Brenner and Rachet, 2004) suggests that for
patients diagnosed during 2000–2001, the national average relative
survival up to 5 years should remain stable (Table 1).
DEPRIVATION
One-year survival has been consistently and significantly higher
for more affluent men. The deprivation gap widened from  5
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average change in the gap every 5 years ( 1.2%) was not itself
statistically significant. For women, the deprivation gap in 1-year
survival is not significant.
There was no significant difference in 5-year survival
among deprivation categories for men diagnosed during
1986–1990. The deprivation gap of þ3.4% in 5-year survival
among women diagnosed at that time (higher survival in
more deprived women) is unusual, but it was of borderline
statistical significance (Table 2), and the data are well fitted
by a simple linear regression (Figure 2). Furthermore, the positive
deprivation gap in 10-year survival for women diagnosed during
the late 1980s (þ4.6%, higher survival in the most deprived) was
statistically significant at the 1% level.
During the 1990s, however, the more typical deprivation
pattern in 5-year survival emerged between both sexes (negative
gradient; lower survival in the more deprived groups).
The deprivation gap of  5% that has arisen for men diagnosed
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 57.5 (56.1, 58.9) 60.6 (59.3, 61.9) 62.9 (61.5, 64.3) 3.8** (1.2, 6.5) 62.7 (60.8, 64.7)
Women 57.3 (55.8, 58.7) 58.5 (57.2, 59.9) 60.9 (59.4, 62.4) 0.7 ( 2.1, 3.5) 60.5 (58.4, 62.6)
5 years Men 20.8 (19.6, 22.1) 21.6 (20.5, 22.8) 25.6 (23.8, 27.4) 4.4** (1.6, 7.3) 25.8 (23.9, 27.8)
Women 20.6 (19.4, 21.9) 20.4 (19.3, 21.6) 23.8 (22.0, 25.6) 5.8** (3.0, 8.7) 24.3 (22.3, 26.3)
10 years Men 9.9 (8.9, 11.0) 10.7 (9.5, 12.0) 0.7 ( 3.5, 4.9) 14.6 (12.8, 16.6)
Women 9.6 (8.6, 10.6) 9.5 (8.3, 10.7) 3.5 ( 0.4, 7.3) 11.7 (10.0, 13.6)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001. Survival estimated with cohort or
complete approach (1986–1990, 1991–1995, 1996–1999) or hybrid
approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative survival
(%) by sex and calendar period of diagnosis: England and Wales,
adults (15–99 years) diagnosed during 1986–1999 and followed up
to 2001.
Survival from multiple myeloma in England and Wales
B Rachet et al
S111
British Journal of Cancer (2008) 99(S1), S110–S112 & 2008 Cancer Research UKin the late 1990s is of borderline significance. For women, the
positive deprivation gradient in myeloma survival (þ3%,
higher survival in more deprived women) in the late 1980s
had completely reversed by the late 1990s: by then, the deprivation
gap between the most deprived and the most affluent women
(almost  8%, lower in more deprived women) had become
statistically significant at 5%. The rate at which the deprivation
gap in 5-year survival for women has widened ( 5.6% every 5 years)
is itself significant (Table 2). Figure 2 illustrates these wide
differences among deprivation groups in survival trends, with no
improvement at all in 5-year survival among the most deprived
group, but an increase of more than 10% for the most affluent
group, in which survival has now overtaken that in the most deprived
group.
Short-term predictions with hybrid analysis suggest that the
wide socioeconomic differences in survival are not likely to reduce
in the near future (Table 2).
COMMENT
Despite substantial overall gains in survival from multiple
myeloma, both short-term and long-term survival remains poor.
Even for patients diagnosed 2000–2001, survival is predicted to be
below 30% at 5 years, and below 15% at 10 years after diagnosis.
The improvement has been small or negligible among the most
deprived groups. As a result, the deprivation gaps in relative
survival widened during the 1990s, even after changes in
background mortality were adjusted for separately, within each
deprivation group.
One-year survival began increasing in the late 1980s, as did the
corresponding deprivation gap. A similar pattern is seen for 5-year
survival only from the mid-1990s. Long-term survival had not
changed until recently, but it is predicted to rise for patients
diagnosed during 2000–2001. This pattern may reflect the
increasing influence of autologous bone marrow graft and stem
cell transplantion, important therapeutic advances introduced
from the late 1980s and early 1990s (Richardson et al, 2004). The
use of drugs such as thalidomide is too recent to have had any
effect on survival figures in this study.
In 1986–1990, both incidence and survival were similar in all
deprivation groups. The more marked increase in both incidence
and survival among the more affluent groups may suggest that
these groups have taken more advantage of earlier diagnosis. Early
diagnosis has considerable prognostic significance, as autograft is
more successful if done at an early stage.
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Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  5.3* ( 9.3,  1.2)  5.1** ( 8.8,  1.3)  7.6** ( 11.5,  3.6)  1.2 ( 4.2, 1.8)  7.1* ( 12.7,  1.5)
Women  2.4 ( 6.6, 1.8)  2.4 ( 6.3, 1.5) 0.4 ( 3.9, 4.7) 1.4 ( 1.7, 4.6) 0.2 ( 5.9, 6.4)
5 years Men 0.4 ( 3.2, 4.1)  3.1 ( 6.6, 0.4)  4.8 ( 10.0, 0.4)  2.8 ( 6.1, 0.4)  6.7* ( 12.3,  1.1)
Women 3.4 ( 0.3, 7.0)  1.6 ( 5.1, 1.8)  7.7** ( 12.9,  2.6)  5.6** ( 8.8,  2.4)  5.8 ( 11.7, 0.1)
10 years Men 1.2 ( 1.8, 4.2) 1.3 ( 2.3, 4.9) 0.1 ( 4.6, 4.8)  4.1 ( 9.5, 1.3)
Women 4.6** (1.9, 7.4) 0.4 ( 3.1, 3.9)  4.3 ( 8.7, 0.2)  2.7 ( 7.7, 2.3)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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